Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload
- Publication date
- 1 July 2006
- Publisher
- Fondazione Ferrara Storti